Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Net Margin (2024 - 2025)

Prime Medicine filings provide 2 years of Net Margin readings, the most recent being 5498.69% for Q4 2025.

  • On a quarterly basis, Net Margin fell 356209.0% to 5498.69% in Q4 2025 year-over-year; TTM through Dec 2025 was 4342.44%, a 222417.0% increase, with the full-year FY2025 number at 4342.44%, up 222417.0% from a year prior.
  • Net Margin hit 5498.69% in Q4 2025 for Prime Medicine, down from 4129.14% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 1936.6% in Q4 2024 to a low of 25128.23% in Q3 2024.